MiQuest Oncology | GSK US Medical Affairs

American Society of Hematology (ASH) 2022

December 10-13, 2022 | New Orleans, LA

Posters

GSK Sponsored Studies

1. POSTER: Single-agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 trial

2. POSTER: Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment

3. POSTER: Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified by Exposure to Lenalidomide or Anti-CD38 Therapy and Double-class Refractory Status: A Retrospective Electronic Health Record Database Study

4. POSTER: Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study

5. POSTER: Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study

6. POSTER: Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum

7. POSTER: Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib

8. POSTER: The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study

9. POSTER: Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

10. POSTER: The Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the United States

11. PUBLICATION ONLY: The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World

12. PUBLICATION ONLY: Efficacy and Safety of Third-line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review

13. PUBLICATION ONLY: Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe

14. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies

15. PUBLICATION ONLY: STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples

Supported Collaborative Studies

1.POSTER: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network (Presentation Posted With Permission)

2. POSTER: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma(Presentation Is Not Available Due to Copyright)

3. POSTER: Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (Presentation Is Not Available Due to Copyright)

4.POSTER: Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma (Presentation Posted With Permission)

5.POSTER: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort (Presentation Posted With Permission)

6. POSTER: Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real world single center experience (Presentation Is Not Available Due to Copyright)

7. PUBLICATION ONLY: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Investigator Sponsored Studies

1.POSTER: Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: results from the phase II, open label, multicenter, GEM-BELA-VRd trial (Presentation Posted With Permission)

2.PUBLICATION ONLY: Phase 2 Study of BeLAntamab Mafodotin as Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission

American Society of Hematology (ASH) 2022

December 10-13, 2022 | New Orleans, LA

Oral Presentations

GSK Sponsored Studies

1. ORAL PRESENTATION: No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

2. ORAL PRESENTATION: Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

3. ORAL PRESENTATION: Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

Posters

Apr 27, 2020 | Virtual Annual Meeting I

1. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses

2. Poster with Audio: Voice Recording: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses

Symposia

Nov 13-15, 2020 | Virtual

The Journey Towards Controlled Asthma: Shifting the Treatment Paradigm

Investigating the Role of Eosinophils in Health, Airway Diseases, and Hypereosinophilic Disorders

Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease

Symposia

Mar 13-16, 2020 | Philadelphia, PA (Cancelled due to COVID-19)

Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pathogenesis, Diagnosis, and Management

The Role of Eosinophilic and Their Potential Heterogeneity in Airways Disease

Uncontrolled Asthma: Changing the Patient Experience

Symposia

January 15-17, 2021 | Virtual

SYMPOSIUM: Advances in Targeting of B-cell Maturation Antigen (BCMA) as an Investigational Novel Approach in Multiple Myeloma

Symposia

April 20, 22, 27, 29, 2021 | Virtual

1. SYMPOSIUM: Managing immune-related adverse events with checkpoint inhibitors

Posters

January 15-17, 2021 | Virtual

1. POSTER: ENGOT-OV44/FIRST Study: A Randomized, Double-Blind, Adaptive, Phase 3 Study of Platinum-Based Chemotherapy (CT) ± Dostarlimab Followed by Niraparib ± Dostarlimab Maintenance as First-Line (1L) Treatment of Stage 3 or 4 OC

2. POSTER: Niraparib Exposure-Response Relationship in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC)

3. POSTER: Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study

4. POSTER: Pharmacokinetics and Safety Following a Single Oral Dose of Niraparib in Patients with Moderate Hepatic Impairment

5. POSTER: ENGOT-EN6/NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin-Paclitaxel Versus Placebo + Carboplatin-Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer (EC)

6. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin– Paclitaxel Versus Placebo + Carboplatin–Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer

7. POSTER: Belantamab Mafodotin (GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics in DREAMM-2

8. POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM)

9. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment

10. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: What Were the Effects of Belantamab Mafodotin in Patients With Multiple Myeloma and Reduced Kidney Function?

11. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs

12. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments

13. POSTER: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

14. POSTER: INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors

15. POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

16. POSTER: Updated Analysis of the Inducible T Cell Co-Stimulatory Receptor (ICOS) Agonist, GSK3359609 (GSK609), Combination with Pembrolizumab (pembro) in Patients (pts) with Anti-PD-1/L1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma (HNSCC)

17. ENCORE: Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

18. ENCORE: Safety and activity of autologous T cells with enhanced NY-ESO-1–specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-E)

19. POSTER: BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II study

20. POSTER: Two-Year Follow-Up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, for Second-Line (2L) Treatment of Non-Small Cell Lung Cancer (NSCLC)

21. PUBLICATION ONLY: Real-World Treatment Patterns of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Patients Missing Out?

22. PUBLICATION ONLY: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting

23. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab

24. PUBLICATION ONLY: DREAMM-1: Patient Perspectives from the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM)

25. PUBLICATION ONLY: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma

26. PUBLICATION ONLY: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review

27. PUBLICATION ONLY: Qualitative Patient Interviews on Symptoms and Impacts in Metastatic Synovial Sarcoma (mSS)

28. PUBLICATION ONLY: Epidemiology of Adenoid Cystic Carcinoma in the United States

Oral Presentations

January 15-17, 2021 | Virtual

1. ORAL PRESENTATION: Safety and efficacy of anti-PD-1 antibody dostarlimab in patients with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study

Oral Presentations

September 7-10, 2019

1. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1)

2. Phase 2, Multi Arm Study of Niraparib in Combination With a PD 1 Inhibitor in Patients With Non Small Cell Lung Cancer: JASPER

Belantamab mafodotin:

Cancer Target Rationale

B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival.^1-4

Overview

Belantamab mafodotin is the first BCMA-targeted antibody-drug conjugate with a humanized anti-BCMA monoclonal antibody (mAb) conjugated to the microtubule inhibitor mafodotin.^2,5
Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism. Mafodotin delivered to BCMA-expressing malignant cells inhibits microtubule polymerization, resulting in immune-independent apoptosis that is accompanied by release of markers of immunogenic cell death (ICD), which may contribute to an adaptive immune response. The antibody component of belantamab mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP).^2,5

References:

Tai Y-T, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7(11):1187-1199.
Tai Y-T, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128-3138.
O’Connor BP, Raman VS, Erikson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199(1):91-98.
Cho S-F, Anderson KC, Tai Y-T. Targeting B-cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821.
Montes de Oca R, Bhattacharya S, Vitali N, et al. The anti-BCMA antibody-drug conjugate belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated anti-tumor response, and in combination with an OX40 agonist potentiates in vivo activity. Presented at: European Hematology Association (EHA) Annual Meeting; June 13-16, 2019; Amsterdam, Netherlands.

Dostarlimab

Cancer Target Rationale

Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that interacts with the PD-1 ligands PD-L1 and PD-L2 to limit T-cell–mediated immune responses.¹
PD-L1 is expressed by many tumor types and is linked to poor clinical outcomes in a variety of cancers.¹

Overview

Dostarlimab is a humanized anti–PD-1 mAb that binds with high affinity to PD-1 and effectively blocks interactions with PD-L1 and PD-L2.
Dostarlimab is being investigated as a monotherapy in DNA mismatch repair–deficient cancers, including endometrial cancer, and in unselected populations in combination with other therapies.

References:

Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47(5):765-779.

ICOS Agonist IgG4 Antibody

Cancer Target Rationale

Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses.¹

Overview

GSK3359609 is an IgG4 ICOS agonist antibody that is designed to enhance T-cell function and enable antitumor responses without depletion of ICOS-expressing cells.^2,3
GSK3359609 is being actively evaluated in a number of clinical trials in solid tumors, including head and neck squamous cell carcinoma and NSCLC either as monotherapy or in combination with currently available immunomodulatory agents and anticancer therapies.

References:

Amatore F, Gorvel L, Olive D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. Expert Opin Ther Targets. 2018;22(4):343-351
Angevin E, Barnette MS, Bauer TM, et al. INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors. J Clin Oncol. 2017;35(15):suppl TPS3113.
Brett S, Yadavilli S, Seestaller-Wehr L, et al. Nonclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. Poster presented at: The European Society for Medical Oncology Annual Congress; October 19-23, 2018; Munich, Germany: Poster 1840P.

TIM-3 Antagonist Antibody (Cobolimab)

Cancer Target Rationale

T-cell immunoglobulin and mucin domain-3 (TIM-3), is a negative regulatory checkpoint molecule that regulates T-cell exhaustion, dampens the antitumor immune response, and may promote tumor cell migration and invasion.¹

Overview

Cobolimab is a humanized TIM-3 antagonist immunoglobulin G4 (IgG4) mAb being investigated as a monotherapy and in combination with dostarlimab and TSR-033 in advanced solid tumors, including melanoma, NSCLC, and colorectal cancer.

References:

Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(1):97-111.

LAG-3 Antagonist Antibody (TSR-033)

Cancer Target Rationale

Lymphocyte activation gene-3 (LAG-3) negatively regulates T-cell activity and, in combination with PD-1, mediates T-cell exhaustion.¹

Overview

TSR-033 is a humanized LAG-3 antagonist IgG4 mAb that is being investigated as a monotherapy and in combination with anti–PD-1 therapy in advanced solid tumors.

References:

Andrews LP, Marciscano AE, Drake CG, Vignali DAA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80-96.

STING Agonist (GSK3745417)

Cancer Target Rationale

Stimulator of interferon genes (STING) is a key adapter molecule that mediates sensing of cytosolic DNA and activates T-cell–dependent tumor immunity.¹

Overview

GSK3745417 is a synthetic STING agonist that is being investigated as a monotherapy and in combination with pembrolizumab in relapsed/refractory solid tumors.

References:

Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016;126(7):2404-2411

Bintrafusp Alfa Bifunctional TGF-β “Trap”/Anti-PD-L1 Fusion Protein

Cancer Target Rationale

Overview

Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor β receptor II (TGF-βRII or TGF-β “trap") fused via a flexible linker to the C-terminus of each heavy chain of the IgG1 antibody blocking PD-L1. Bintrafusp alfa is designed to allow for targeting tumor cells via two nonredundant immunostimulatory mechanisms—the TGF-β and PD-L1 pathways.^1,2
It is being investigated as monotherapy and in combination with other anticancer agents in various malignancies.

References:

Knudson KM, Hicks KC, Luo X, Chen J-Q, Schlom J, Gameiro SR. M7824, a novel bifunctional anti-PD-L1/TGF trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. Oncoimmunology. 2018;7(5):e1426519.
Lan Y, Zhang D, Xu C, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-ß. Sci Transl Med. 2018;10(424):eaan5488.

OX40 Agonist Antibody (GSK3174998)

Cancer Target Rationale

Tumor necrosis factor receptor superfamily, member 4 (OX40 [CD134]) is expressed by T cells during antigen-specific priming.¹

Overview

GSK3174998 is a humanized immunoglobulin 1 (IgG1) OX40 agonist antibody that can enhance the proliferation and survival of CD4+ and CD8+ T cells and deplete tumor-infiltrating regulatory T cells via antibody-dependent cell cytotoxicity or phagocytosis.^1,2
GSK3174998 is being investigated in combination with other anticancer agents in multiple tumor types

References:

Linch SN, McNamara MJ, Redmond WL. OX40 agonists and combination immunotherapy: putting the pedal to the metal. Front Oncol. 2015;5:34
Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer. 2016;52:50-66

Belantamab Mafodotin - Anti-BCMA Immunoconjugate

Cancer Target Rationale

Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is involved in driving necroptosis, a proinflammatory form of cell death that may promote metastasis and suppress T-cell–driven antitumor immunity.^1,2

Overview

GSK3145095 is a small-molecule RIPK1 inhibitor.

References:

Najafov A, Chen H, Yuan J. Necroptosis and cancer. Trends Cancer. 2017;3(4):294-301.
Seifert L, Werba G, Tiwari S, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature. 2016;532(7598):245-249.

NY-ESO-ImmTAC (IMCnyeso)

Cancer Target Rationale

New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and cancer-testis antigen 2 (LAGE-1a) are immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients.^1,2
NY-ESO-1 and LAGE-1a are widely expressed in diverse tumor types with restricted expression in normal tissues.¹

Overview

NY-ESO-ImmTAC (immune mobilizing monoclonal TCR against cancer [IMCnyeso]) is a bifunctional soluble high-affinity T-cell receptor (TCR) specific for NY-ESO-1 that also engages the CD3 receptor on T cells.³
It is being studied as a monotherapy in advanced NY-ESO-1– and/or LAGE-1a–positive cancers.

References:

Thomas R, Al-Khadairi G, Roelands J, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol. 2018;9:947.
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914-921.
McCormack E, Adams KJ, Hassan NJ, et al. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother. 2013;62(4):773-785.

Anti-CD96 Antibody (GSK6097608)

Cancer Target Rationale

CD96 is an immune checkpoint protein expressed on T cells and natural killer (NK) cells in multiple tumor types.^1,2,3
CD96 effectively competes with CD226 for binding to a shared ligand, CD155, to modulate immune responses and promote tumor cell immune evasion.^1,2,3

Overview

GSK6097608 inhibits the binding of CD96 to CD155 and activates T cells and NK cells, which enhances antitumor activity.^1,3
GSK6097608 is a first-in-class anti-CD96 IgG1 monoclonal antibody being investigated as a monotherapy and in combination with dostarlimab (anti-PD1 antibody) in advanced solid tumors.⁴

References:

Blake SJ, Stannard K, Liu J, et al. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 2016;6(4):446-459.
Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. Front Immunol. 2018;9:1072. doi:10.3389/fimmu.2018.01072.
Mittal D, Lepletier A, Madore J, et al. CD96 is an immune checkpoint that regulates CD8+ T-cell antitumor function. Cancer Immunol Res. 2019;7(4):559-571.
ClinicalTrials.gov. https://clinicaltrials.gov/. Accessed July 9, 2020.
^§In collaboration with 23andMe

Molibresib BET Inhibitor

Cancer Target Rationale

Bromodomain and extraterminal (BET) proteins bind to acetylated lysines in histone tails and other nuclear proteins to regulate the epigenetic landscape.¹
They directly regulate expression of many cancer-related genes, including c-MYC.¹

Overview

Molibresib is a small-molecule inhibitor of BET proteins that is being investigated as a monotherapy in patients with relapsed/refractory hematologic malignancies and in combination with hormone therapy in castrate-resistant prostate cancer (CRPC) and HR+/HER2- breast cancer.²

References:

Pérez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. Epigenetics. 2017;12(5):323-339.
Dawson M, Stein EM, Huntly BJP, et al. A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML). Blood. 2017;130(suppl 1): 1377.

PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715)

Cancer Target Rationale

GSK is investigating the activity of two compounds that target protein arginine methyltransferases (PRMTs).
PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53.^1,2

Overview

GSK3326595, a selective inhibitor of PRMT5, is being investigated as a monotherapy in solid tumors and in combination with other therapies in various hematologic malignancies.
GSK3368715, a type 1 PRMT inhibitor, is being investigated in phase I trials for patients with diffuse large B-cell lymphoma and solid tumors.³

References:

Smith E, Zhou W, Shindiapina P, Sif S, Li C, Baiocchi RA. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. Expert Opin Ther Targets. 2018;22(6):527-545.
Poulard C, Corbo L, Le Romancer M. Protein arginine methylation/demethylation and cancer. Oncotarget. 2016;7(41):67532-67550.
Fedoriw A, Rajapurkar SR, O’Brien S, et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Cancer Cell.2019;36(1):100-114.

PI3Kβ Inhibitor (GSK2636771)

Cancer Target Rationale

The phosphoinositide 3-kinase (PI3K)/protein kinase ß (AKT) signaling pathway plays a major role in regulating cellular process involved in cancer, including proliferation, growth, survival, and migration.^1,2
The PI3K/AKT and phosphatase and tensin homolog (PTEN) pathways are among the most frequently mutated pathways in human cancers.²

Overview

GSK is investigating a PI3Kß inhibitor, GSK2636771, in combination with enzalutamide, in PTEN-deficient metastatic castration-resistant prostate cancer (mCRPC).

References:

Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. Int J Mol Sci. 2015;16(9):21138-21152.
Stark A-K, Sriskantharjah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharmacol. 2015;23:82-91.

Niraparib (PARP Inhibitor)

Cancer Target Rationale

Poly ADP ribose polymerases (PARPs) are a family of enzymes involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs.¹
PARP inhibition induces cell death through synthetic lethality.¹

Overview

Niraparib is a selective PARP1/2 inhibitor approved as monotherapy for the maintenance treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.^2,3
Niraparib is being investigated as a monotherapy and in combination with other anticancer agents, including dostarlimab, in breast cancer, ovarian cancer, and advanced NSCLC.

References:

Gupte R, Liu Z, Kraus WL. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Genes Dev. 2017;31(2):101-1261. Gupte R, Liu Z, Kraus WL. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Genes Dev. 2017;31(2):101-126.
Zejula [summary of product characteristics]. Amsterdam, Netherlands: TESARO Bio Netherlands BV; 2019.
ZEJULA [package insert]. Waltham, MA: TESARO, Inc; 2019.

You will now be taken from the GSK U.S. Medical Affairs portal to a separate website maintained by GlaxoSmithKline.

Accept Decline

European Society for Medical Oncology (ESMO)

Oral Presentations

October, 2018

Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer

A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study

Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the Anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer

European Society for Medical Oncology (ESMO)

Posters

October, 2018

1. Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody

2. First in Human Study with GSK3359609, Inducible T cell Co-stimulator Receptor Agonist in Patients with Advanced, Solid Tumors: Preliminary Results from INDUCE-1

3. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer

4. A Phase 2, Single Arm, Open Label Study to evaluate the safety and efficacy of niraparib combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer following frontline platinum-based chemotherapy with bevacizumab (OVARIO)

5. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study

6. A Retrospective Analysis of Real-World Tumor BRCA (tBRCA) Testing Trends in Ovarian Cancer (OC) Before and After PARP Inhibitor Approvals

7. Brain Metastases in Primary Ovarian Cancer: Real-world Data

Society for Immunotherapy of Cancer (SITC)

Oral Presentations

November, 2018

1. A Phase 1 study of TSR-022, an Anti-TIM-3 monoclonal antibody, in combination with TSR-042 (Anti-PD-1) in patients with colorectal cancer and Post-PD-1 NSCLC and melanoma

Society for Immunotherapy of Cancer (SITC)

Posters

June, 2019

1. A Phase 1 study of TSR-022, an Anti-TIM-3 monoclonal antibody, in combination with TSR-042 (Anti-PD-1) in patients with colorectal cancer and Post-PD-1 NSCLC and melanoma

2. A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

3. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC

4. The anti-tumor efficacy of TIM-3 blockade in a murine model of sarcoma

CROI 2022

February 12-16, 2022 | Virtual

Oral Presentations

1. ORAL PRESENTATION: Shapiro A, et al. Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression

2. ORAL PRESENTATION: Kohli A, et al. Intramuscular Sotrovimab is Noninferior to Intravenous Sotrovimab For COVID-19

Posters

September 29 - October 3, 2021 | Virtual

1. POSTER: Early COVID-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab

IDWeek 2022

October 19-23, 2022 | Washington, DC

Posters

1. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation.

2. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. Analysis of Co-Resistance Among Escherichia coli Urine Isolates From Female Outpatients in the United States.

3. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. Analysis of Co-Resistance Among Klebsiella pneumoniae Urine Isolates From Female Outpatients in the United States.

4. POSTER: Trennery CL, Martin S, Kosa K, et al. Patient Perceptions of Treatment Success in Uncomplicated Urinary Tract Infection.

ECCMID 2022

April 23-26, 2022 | Lisbon, Portugal

Oral Presentations

1. ORAL PRESENTATION: Satram S, et al. Patient-reported symptom outcomes from COMET-ICE, a phase III study of sotrovimab for early treatment of non-hospitalized patients with COVID-19.

ECCMID 2022

April 23-26, 2022 | Lisbon, Portugal

Posters

1. POSTER: Subramanian S, et al. Resistance analysis in the COMET-ICE study: sotrovimab treatment in participants with mild-to-moderate COVID-19.

Oral Presentations

November 4-7, 2021 | Virtual

1. Singh AK, et al. ASCEND-ID: Daprodustat is Non-Inferior to Darbepoetin Alfa in Treating Anemia in Incident Dialysis Patients

2. Singh AK, et al. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients

3. Singh AK, et al. Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial

4. Singh AK, et al. ASCEND program: efficacy and safety from ASCEND-D and –ND, and overall MACE findings

Posters

November 4-7, 2021 | Virtual

1. Bell CF, et al. Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. Abstract Publication No. PO1437

2. Bell CF, et al. Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. Abstract Publication No. PO2409

3. Singh AK, et al. ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. Poster No. PO0465

4. Coyne DW, et al. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. Poster No. PO0487

ASN 2022

November 3-6, 2022 | Orlando, FL

Posters

1. Keeley T, et al. Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease

2. Keeley T, et al. Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD

3. Johansen K, et al. Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial

4. Jha V, et al. Hemoglobin Stability in the ASCEND-D and ND trials

5. Waikar SS, et al. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial

6. Richards A, et al. Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment

7. Dasgupta, I et al. Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial

8. Coyne, D et al. Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial

9. Singh, AK et al. Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial

10. Requena, G et al. Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France

11. Singh, AK et al. On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents – Post hoc Analyses of ASCEND-ND and ASCEND-D

ASN 2022

November 3-6, 2022 | Orlando, FL

Oral Presentations

1. Obrador GT, et al. Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of MACE in the ASCEND Trials

ERA

May 19-22, 2022 | Paris | Virtual

Oral Presentations

1. Obrador GT, et al. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial.

2. Singh AK, et al. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial.

3. Singh AK, et al. Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials.

4. Lu E, et al. Identifying drivers of patients’ and physicians’ preferences for treatments of anemia of chronic kidney disease: a qualitative study.

5. Gowrisankar S, et al. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis.

NKF

April 6-10, 2022 | Boston, MA

Posters

1. Singh AK, et al. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials.

NKF

April 6-10, 2022 | Boston, MA

Oral Presentations

1. Singh AK, et al. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Poster No. 373

AMCP 2022

March 29 - April 1, 2022 | Chicago

Posters

1. POSTER: Marijam A, et al. Cost-effectiveness evaluation of sotrovimab, a monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in patients at high risk of disease progression.

2. POSTER: Lokhandwala et al. Within trial cost analysis of resource use from a phase 3 clinical trial evaluating sotrovimab for the treatment of COVID-19 patients at high risk of progression

European League Against Rheumatism (EULAR)

Oral Presentations

June, 2019

1. GSK3196165 An investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis

2. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab

European Alliance of Associations for Rheumatology (EULAR)

June 1-4, 2022 | Hybrid | Copenhagen, Denmark

Oral Presentations

1. ORAL PRESENTATION: Pharmacodynamic Effect of Sequential Belimumab and Rituximab Therapy in Patients with SLE: BLISS-BELIEVE Study

European Alliance of Associations for Rheumatology (EULAR)

June 1-4, 2022 | Hybrid | Copenhagen, Denmark

Posters

1. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE

2. POSTER: Evaluation of cCRESS in Phase 2 Randomised Placebo-controlled Study of Sequential Belimumab/Rituximab Administration in Patients with Primary Sjogren's Syndrome

3. POSTER: Year 4 Observational Follow up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE who Completed a Phase 4, 52-week, Randomised, Double-blind Placebo-controlled Safety

4. POSTER: Effect of Belimumab on SRI-4 Response in Multiple Subgroups of Patients with SLE: Results of Large Integrated Analysis

IASLC WCLC 2022

August 6-9, 2022 | Vienna, Austria | Virtual

Posters

1. POSTER: Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung COSTAR

2. POSTER: Phase 2 platform trial of anti-T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) GSK’859A/EOS-448 plus anti-programmed death-1 (PD-1) dostarlimab in patients with non-small cell lung cancer (NSCLC)

European Hematology Association (EHA)

June 9-12, 2022 | Vienna, Austria | Virtual

Posters

1. POSTER: DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma

2. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis

3. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study

4. POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS)

5. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination With a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study

6. PUBLICATION ONLY: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma: DREAMM-14

American Society of Clinical Oncology (ASCO) 2022

June 3-7, 2022 | Chicago, IL | Virtual

Posters

1. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM]

2. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis

3. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination with a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study

4. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study

5. POSTER: Exploring Alternative Dosing Regimens of Single-agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14

6. POSTER: MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC)

7. POSTER: Real-World Trends of PARPi Maintenance Treatment Uptake and Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC) in the US

8. POSTER: Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial vs an external control arm from the Flatiron Health database

9. POSTER: Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study

10. POSTER: Patient-reported outcomes from the GARNET trial in patients with advanced or recurrent mismatch repair deficient colorectal cancer: a post hoc subgroup analysis

11. POSTER: ZENYTH-ESO: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296]

12. POSTER: AMBER Parts 1C and 1E: a Phase 1 Study of Cobolimab plus Dostarlimab in Patients with Advanced/Metastatic Melanoma

13. PUBLICATION ONLY: Treatment patterns and time to next treatment among patients with OC in a real-life setting in Finland: the OCRWE-Finland study

14. PUBLICATION ONLY: Quality Assurance in Ovarian Cancer (QS-OVAR)

15. PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons

16. PUBLICATION ONLY: Understanding patient characteristics, treatment patterns, and clinical outcomes for advanced and recurrent endometrial cancer in Alberta, Canada

17. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials

International Myeloma Society (IMS)

August 25-27, 2022 | Los Angeles, CA

Posters

1. POSTER: Real-World Belantamab Mafodotin (Belamaf) Use: A US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment

European Society for Medical Oncology (ESMO)

September 9-13, 2022 | Paris, France

Oral Presentations

GSK Sponsored Studies

1. ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors

2. ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients

International Congress on Myeloproliferative Neoplasms (MPN)

October 27-28, 2022 | Brooklyn, NY

Posters

GSK Sponsored Studies

1. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor (Encore)

2. POSTER: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] (Encore)

Posters

GSK Sponsored Studies

October 27-28, 2022 | Brooklyn, NY

1. ABSTRACT ONLY: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS)

2. ABSTRACT ONLY: Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression

3. ABSTRACT ONLY: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts

International Gynecologic Cancer Society (IGCS)

September 29-October 1, 2022 | New York, NY

Oral Presentations

GSK Sponsored Studies

1. ORAL PRESENTATION: Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab

Society for Neuro-Oncology (SNO) 2022

November 16-20, 2022 | Tampa, FL

Oral Presentations

Supported Collaborative Study

1. ORAL PRESENTATION: A phase 0 trigger trial of Niraparib in newly-diagnosed glioblastoma patients (Presentation Posted With Permission)

International Gynecologic Cancer Society (IGCS)

September 29-October 1, 2022 | New York, NY

Posters

GSK Sponsored Studies

1. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022)

2. POSTER: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab in the GARNET Study

3. POSTER: Immune-Related Endpoints in Patients with Advanced or Recurrent Endometrial Cancer Treated with Dostarlimab in the GARNET Study

4. POSTER: Optimization of Assessment of Disease Progression Between Blinded Central Independent Review and Investigator Assessment in the PRIMA/ENGOT-ov26/GOG-3012 Trial

5. POSTER: Impact of Initiation Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer

6. POSTER: Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 ad-hoc subgroup analysis

7. POSTER: Adoption of New First-line Maintenance Strategies Among Patients with Primary Advanced Ovarian Cancer After Food and Drug Administration Approval

8. POSTER: First-line Maintenance Among Advanced Ovarian Cancer Patients in The US Oncology Network: A Real-world Retrospective Cohort Study

9. POSTER: Physician-reported Patient Involvement in 1L Ovarian Cancer Treatment, Including Maintenance, in the US and Europe: A Real-World Chart Review Analysis (2017–2020)

Society of Hematologic Oncology (SOHO)

September 28-October 1, 2022 | Houston, TX

Oral Presentations

GSK Sponsored Studies

1. ORAL PRESENTATION: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore)

Society for Immunotherapy of Cancer (SITC) 2022

November 8-12, 2022 | Boston, MA

Posters

GSK Sponsored Studies

1. POSTER: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS)

2. POSTER: Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression

3. POSTER: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts

Society of Hematologic Oncology (SOHO)

September 28-October 1, 2022 | Houston, TX

Posters

GSK Sponsored Studies

1. POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population

2. POSTER: Real-World Belantamab Mafodotin (Belamaf) Use: A US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment (Encore)

3. POSTER: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): DREAMM-14 (Encore)

4. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore)

5. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM](Encore)

6. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor(Encore)

European Society of Gynaecological Oncology (ESGO)

October 27-30, 2022 | Berlin, Germany

Posters

GSK Sponsored Studies

1. POSTER: First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort

2. POSTER: Treatment patterns and time to next treatment among OC patients in a real-life setting in Finland: the OCRWE-Finland study (ASCO Encore)

3. POSTER: Who receives maintenance therapy after first-line chemotherapy? A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States

4. POSTER: Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy?

5. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS ENCORE)

6. POSTER: Ovarian Cancer Retrospective European (O’CaRE) Observational Study: Analysis of First-Line (1L) Outcomes in Patients With Ovarian Cancer (OC) Stratified by Number of Risk Factors for Progression

7. POSTER: A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial

8. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial (AACR ENCORE)

9. POSTER: Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study (ESMO ENCORE)

10. POSTER: Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab (IGCS ENCORE)

11. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE)

12. POSTER: Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study (IGCS ENCORE)

Investigator Sponsored Studies

1.POSTER: AGO-OVAR 28 / ENGOT-ov57: Niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) (Presentation Posted With Permission)

2.POSTER: Characterization of long term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO / A-AGO (Presentation Posted With Permission)

3.POSTER: Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (Presentation Posted With Permission)

World Cornea Congress (WCC)

September 28-29, 2022 | Chicago, IL

Oral Presentations

GSK Sponsored Studies

1. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin

World Cornea Congress (WCC)

September 28-29, 2022 | Chicago, IL

Posters

GSK Sponsored Studies

1. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment

European Society for Medical Oncology (ESMO)

September 9-13, 2022 | Paris, France

Posters

International Myeloma Society (IMS)

August 25-27, 2022 | Los Angeles, CA

Oral Presentations

1. ORAL PRESENTATION: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)

American Society of Clinical Oncology (ASCO) 2022

June 3-7, 2022 | Chicago, IL | Virtual

Oral Presentations

1. ORAL PRESENTATION: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

2. ORAL PRESENTATION: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)

3. ORAL PRESENTATION: Primary Efficacy and Safety of letetresgene autoleucel (lete-cel; GSK3377794) Pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS)

4. ORAL PRESENTATION: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study

European League Against Rheumatism (EULAR)

Oral Presentations

June, 2019

1. Pooled analysis of the real-world effectiveness of belimumab in treatment of systemic lupus erythematosus using multi-country data from the OBSErve studies

2. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus

3. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab

European League Against Rheumatism (EULAR)

Oral Presentations

June, 2019

1. GSK3196165 An investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis

European League Against Rheumatism (EULAR)

Oral Presentations

June, 2019

1. Pooled analysis of the real-world effectiveness of belimumab in treatment of systemic lupus erythematosus using multi-country data from the OBSErve studies

2. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus

CHEST 2022

October 16-19, 2022 | Nashville, TN

PRESENTATIONS BY GSK ASSOCIATED WITH TRELEGY:

Asthma

1. Bogart M, Germain G, Laliberté F, et al. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US.

2. Busse W, Chupp G, Stanaland M, et al. CAPTAIN: Effects of age as a continuous variable on asthma control.

PRESENTATIONS BY GSK ASSOCIATED WITH BREO:

Asthma

1. Goodall E, Wood R, Numbere B, et al. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs).

PRESENTATIONS BY GSK ASSOCIATED WITH CLASSIC AND ESTABLISHED PRODUCTS:

Asthma

1. Pitrez P, Bruselle G, Yorgancıoğlu A, et al. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication.

ACAAI 2022

November 10-14, 2022 | Louisville, KY

POSTERS BY GSK ASSOCIATED WITH NUCALA:

Chronic Rhinosinusitis with Nasal Polyps

1. Desrosiers M, Diamant Z, Castelnuovo P, et al. Sustained Clinical Benefits in Patients With Chronic Rhinosinusitis With Nasal Polyps 24 Weeks Post-mepolizumab Treatment.

Severe Eosinophilic Asthma

1. Pollard S, Offenberger J, Lee FE-H, et al. The Sustained OCS-Sparing Effect of Mepolizumab: Results From the Real-World REALITI-A Study at 2 Years.

2. Silver J, Steffens A, Chastek B, et al. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma.

Hypereosinophilic Syndrome

1. Silver J, Strobel MJ, Gratie D, et al. Patients’ perspective on the burden of Hypereosinophilic Syndrome.

All Indications

1. Strobel MJ, Alves D, Roufosse F, et al. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights.

ACR 2022

November 10-14, 2022 | Philadelphia, PA

POSTERS BY GSK ASSOCIATED WITH NUCALA:

Eosinophilic Granulomatosis with Polyangiitis

1. Hellmich B, Neukirch K, Lukas M, et al. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study.

2. Silver J, Deb A, Packnett E, et al. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Initiating Mepolizumab.

3. Terrier B, Jayne D, Hellmich B, et al. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype.

CHEST 2022

October 16-19, 2022 | Nashville, TN

PRESENTATIONS BY GSK ASSOCIATED WITH NUCALA:

Eosinophilic Granulomatosis with Polyangiitis

1. Silver J, Deb A, Packnett E, et al Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Initiating Mepolizumab.

PRESENTATIONS BY GSK ASSOCIATED WITH TRELEGY:

Asthma

1. Seo J, Zhang S, Krucien N, et al. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy.

2. Seo J, Zhang S, Zhang D, et al. Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma.

PRESENTATIONS BY GSK ASSOCIATED WITH BREO:

Asthma

1. Goodall E, Wood R, Numbere B, et al. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS).

ATS 2022

May 13-18, 2022 | San Francisco, CA

POSTERS BY GSK ASSOCIATED WITH NUCALA:

Severe Eosinophilic Asthma

1. Chupp G, Heaney LG, Pelaia G, et al. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study.

2. Corbridge T, Deb A, Germain G, et al. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US.

3. Corbridge T, Deb A, Packnett E, et al. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma.

4. Domingo Ribas C, Pavord I, Price R, et al. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study.

5. Lee JK, Schleich F, Canonica GW, et al. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study.

6. Lu E, Mu G, Alfonso-Cristancho R. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma.

Nasal Polyps

1. Hwee J, Smith S, Small M, et al. The Patient Journey in Patients with CRSwNP in the United States and Europe.

2. Liu M, Bagnasco D, Matucci A, et al. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study.

3. Smith SG, Price R, Mollo MR, et al. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS.

POSTERS BY GSK ASSOCIATED WITH TRELEGY:

Asthma

1. Bogart M, Bancroft T, Rothnie K, et al. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study.

2. Bogart M, Han X, Bengtson L, et al. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study.

3. Rothnie KJ, Bancroft T, Bogart M, et al. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States.

4. Rothnie K, Han X, Bancroft T, et al. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study.

5. Zhang S, Czira A, Harley J, et al. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US.

COPD

1. Bogart M, Bunner S, Johnson MG, et al. Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD).

2. Bogart M, Bengtson L, Rothnie K, et al. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study.

3. Bogart M, Han X, Bengtson L, et al. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study.

4. Bogart M, Germain G, Laliberté F, et al. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S.

5. Ismaila A, Haeussler K, Czira A, et al. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations.

6. Ismaila A, Haeussler K, Czira A, et al. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis.

7. Rothnie KJ, Bancroft T, Bogart M, et al. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States.

8. Rothnie K, Han X, Bengtson L, et al. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study.

9. Whittaker HR, Rothnie K, Quint JK. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England.

POSTERS BY GSK ASSOCIATED WITH ADVAIR:

1. Chapman KR, Bosnic-Anticevich S, Cano MC, et al. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients’ and Physicians’ peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2).

POSTERS BY GSK ASSOCIATED WITH BREO:

1. Cho E-Y, Cho J-E, Jang S-H, et al. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea.

2. Van der Palen J, Slade D, Verma M, et al. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma.

POSTERS BY GSK ASSOCIATED WITH ANORO:

1. Cho E-Y, Cho J-E, Lee E-B, et al. An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease.

2. Ismaila A, Czira A, Haeussler K, et al. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis.

POSTERS BY GSK ASSOCIATED WITH ARNUITY:

1. Cho E-Y, Lee E-B, Yang S-H, et al. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity® Ellipta™) in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea.

POSTERS BY GSK ASSOCIATED WITH SOTROVIMAB:

1. Gibbons D, Marijam A, Symons JM, et al. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 – A Population Study.

2. Gibbons D, Marijam A, Morel Symons J, et al. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States – A Population Study.

IDWeek

October 19-23, 2022 | Washington, DC

Posters

1. POSTER: A report of the postmarketing spontaneous safety data over 24 years for GSK’s measles-mumps-rubella (MMR) vaccine. Singh T et al.

2. POSTER: Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity and safety results at approximately 10 years after initial vaccination. Strezova A et al.

3. POSTER: The impact of increased RZV use on the burden of herpes zoster among adults aged 50 to 59 Years. Singer D et al.

4. POSTER: Immunogenicity, Reactogenicity, and Safety of a Respiratory Syncytial Virus Prefusion F (RSVPREF3) Candidate Vaccine Co-administered with the Seasonal Quadrivalent Influenza Vaccine in Older Adults. Chandler R et al.

5. POSTER: RSVPreF3 OA Candidate Vaccine Safety Presentation. Schwarz TF et al.

6. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. Schwarz TF et al.

7. POSTER: RSVPreF3 OA Candidate Vaccine Efficacy Presentation. Ison MG et al.

AMCP Nexus

October 11-14, 2022 | National Harbor, MD

Posters

1. POSTER: Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriasis: A Retrospective Cohort Study. Singer D et al.

AAFP FMX

September 20-23, 2022 | Washington, DC

Posters

1. POSTER: Determinants of Meningococcal Vaccination Coverage: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit. Herrera-Restrepo O et al.

American Thoracic Society (ATS)

Posters & Oral Presentations

Severe Eosinophilic Asthma

1. Chaudhuri R, Canonica GW, Bals R, et al. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. [Poster No. 714; Abstract A4267].

2. Hahn B, Bogart M, Silver J, et al. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. [Poster No. 804; Abstract A7741].

3. Molfino NA, Averell CM, Hahn BA, et al. Patients with Uncontrolled Asthma Eligible for a Biologic. [Poster No. 801; Abstract A7738].

4. Moore WC, Kornmann O, Humbert M, et al. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. [Oral presentation available here; Abstract A4211].

5. Moraes F, Abreu G, Nogueira T, et al. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. [Poster No. 712; Abstract A1827].

6. Moraes F, Abreu G, Nogueira T, et al. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. [Poster No. 710; Abstract A1825].

7. Verhamme K, de Ridder M, Webb D, et al. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. [Poster No. P792; Abstract A5630].

8. Wu AC, McMahon PM, Mendelsohn A, et al. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. P742; Abstract A4771].

Self-Administration Formulation of Mepolizumab

1. Prazma C, Bernstein D, Brightling C, et al. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. [Poster No. 1301; Abstract A1312].

Eosinophilic Granulomatosis with Polyangiitis

1. Bell CF, Blauer-Peterson C. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. [Poster No. P1286; Abstract A6579].

Hypereosinophilic Syndrome

1. Steinfeld J, Roufosse F, Kahn JE, et al. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. [Oral presentation available here; Abstract A4212].

Asthma

1. Averell CM, Hahn BA, Zografos L, et al. Assessment of Asthma Control in Respiratory Specialist Offices in the US. [Poster No. P711; Abstract A1826].

2. Bogart M, Chastek B, White J, et al. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. [Poster No. P805; Abstract A7742].

3. Davitte J, DeBarmore B, Hinds D, et al. Asthma control among the treated U.S. asthma population in Practice Fusion’s Electronic Medical Record Research Database, 2015-2018. [Poster No. P699; Abstract A1814].

4. Fowler A, Kerstjens HAM, Bailes Z, et al. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. [Poster No. P788; Abstract A5626].

5. Kerstjens HA, Pavord ID, Peachey G, et al. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. [Oral presentation available here; Abstract A4209].

6. Lee LA, Boulet LP, Fowler A, et al. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. [Poster No. P787; Abstract A5625].

7. Molfino NA, Averell CM, Hahn BA, et al. Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. [Poster No. P372; Abstract A6482]

8. Pavord ID, Fowler A, Kerstjens HA, et al. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. [Oral presentation available here; Abstract A6247].

9. Sansbury LB, Hinds D, Chao J, et al. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. [Poster No. P713; Abstract A1828]

10. Tabberer M, von Maltzahn R, Bacci E, et al. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS®: Asthma in Two Clinical Trials of Moderate to Severe Asthma. [Poster No. P786; Abstract A5624]

COPD

1. Anderson M, Drummond MB, Jain R, et al. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. [Poster No. P813; Abstract A4302].

2. Ferguson GT, Brown N, Compton C, et al. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). [Poster No. P806; Abstract A4295].

3. Halpin DMG, Worsley S, Ismaila AS, et al. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. [Poster No. P824; Abstract A4313].

4. Mularski R, Wu B, Fuoco MJ, et al. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. [Poster No. P276; Abstract A4811].

5. Mularski RA, Drummond MB, Jain R, et al. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. [Poster No. P1045; Abstract A5050].

6. Obeid D, Bansal S, Brown N, et al. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. [Poster No. 805; Abstract A4294].

7. Bjermer L, Maltais F, Vogelmeier CF, et al. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. [Poster No. P1091; Abstract A3326].

8. Cole AL, Moretz C, Mu G, et al. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. [Poster No. 817; Abstract A4306].

9. Kerwin EM, Maltais F, Boucot IH, et al. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. [Poster No. 518; Abstract A4579].

10. Kerwin EM, Bjermer L, Maltais F, et al. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. [Poster No. 1089; Abstract A3324].

11. Moretz C, Hahn B, White J, et al. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. [Poster No. 811; Abstract A4300].

12. Vogelmeier CF, Kerwin EM, Naya IP, et al. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. [Poster No. 1053; Abstract A5058].

13. Vogelmeier CF, Boucot IH, Kerwin EM, et al. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. [Poster No. 1090; Abstract A3325].

14. Keir HR, Richardson H, Mayhew D, et al. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. [Poster No. P474; Abstract A3997].

AAAAI

Oral Presentations

1. Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study

AAAAI

Posters

1. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility

2. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Exacerbations.

3. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles

4. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma

5. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients?

6. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma – Meta-analysis From Two Phase 3 Trials.

7. Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis.

8. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count

9. Step-up to High Dose Fluticasone Furoate in Combination With Long-Acting Bronchodilator in Inadequately Controlled Asthma: The CAPTAIN Study

American College of Chest Physicians (CHEST)

Posters

Severe Eosinophilic Asthma

1. Silver J, Bogart M, Molfino N, et al. Reasons why patients with severe asthma discontinue biologic treatment. Poster No. P0018.

2. Silver J, Bogart M, Molfino N, et al. Impact of mepolizumab in patients with life-threatening asthma. Poster No. P0017.

Asthma

1. Nathan R, Boulet L-P, Kerstjens HA, et al. CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting β2-agonist therapy. Poster No. P1483.

2. Ramesh N, Hegewald M, Maselli DJ, et al. Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys. Poster No. P1488.

3. Sule N, Fowler A, Kerstjens HA, et al. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. Oral presentation.

4. Zhang S, White J, Meeraus W, et al. Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting β2-agonist. Poster No. P1512.

COPD

1. Anzueto A, Obeid D, Bansal S, et al. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation. Poster No. P1440.

2. Bogart M, Wu B, Germain G, et al. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. Poster No. P1444.

3. Calverley PMA, Celli BR, Crim C, et al. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. Poster No. P1448.

4. Criner GJ, Barnes N, Brusselle G, et al. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. Poster No. P1454.

5. Dransfield MT, Halpin DMG, Han MK, et al. Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial. Poster No. P1458.

6. Han MK, Bratton DJ, Hartley B, et al. Benefit–risk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model. Oral presentation.

7. Hosking L, Yeo A, Hoffman J, et al. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. Poster No. P1501.

8. Mannino D, Siddall J, Small M, et al. Cross-sectional survey to assess chronic obstructive pulmonary disease (COPD) medication use by United States (US) physicians. Poster No. P1446.

9. Soler X, Siddall J, Small M, et al. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). Poster No. P1445.

10. Slade D, Ray R, Moretz C, et al. Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO). Poster No. 1467.

11. Slade D, Ray R, Moretz C, et al. Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population. Poster No. 1465.

12. Slade D, Ray R, Moretz C, et al. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. Poster No. 1466.

13. McCreary G, Yawn BP, Linnell J, et al. Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network. Poster No. P1481.

14. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018. Poster No. P1505.

AAAAI

Oral Presentation

Mar 13-16, 2020

1. Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study

Posters

Mar 13-16, 2020

1. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility

2. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Exacerbations.

3. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles.

4. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma

5. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients?

6. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma – Meta-analysis From Two Phase 3 Trials.

7. Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis.

8. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count

9. Step-up to High Dose Fluticasone Furoate in Combination With Long-Acting Bronchodilator in Inadequately Controlled Asthma: The CAPTAIN Study

AAAAI 2022

Feb 25–28, 2022 | Phoenix, AZ

POSTERS BY GSK ON NUCALA:

Severe Eosinophilic Asthma

1. Chupp G, Lee JK, Liu MC, et al. Mepolizumab Demonstrates Real-World Clinical Effectiveness in Both Type 2 Biomarker High and Type 2 Biomarker Low Patients With Severe Asthma.[Abstract/Poster No. L81].

2. Bernstein D, Liu MC, Schleich F, et al. The Impact of Baseline Exhaled Nitric Oxide Levels and Blood Eosinophil Count on Clinical Outcomes in REALITI-A.[Abstract/Poster No. P570].

3. Lee JK, Pollard S, Liu MC, et al. Influence of Baseline Total IgE and History of Previous Omalizumab Use on the Impact of Mepolizumab in Reducing Rate of Severe Asthma Exacerbations: Results From the Real-World REALITI-A Study. [Abstract/Poster No. P574].

4. Liu MC, Schleich F, Lee JK, et al. The Clinical Benefit of Mepolizumab Treatment Is Independent of Baseline Maintenance Oral Corticosteroid Use: Results From the Real-World REALITI-A Study. [Abstract/Presentation No. P443].

Eosinophilic Granulomatosis With Polyangiitis

1. Khoury P, Akuthota P, Baylis L, et al. Impact of Baseline Treatment, Duration of Disease, and Refractory Status on Outcomes in Mepolizumab-Treated Patients With EGPA. [Abstract/Poster No. P154].

Nasal Polyps

1. Mullol J, Lund V, Wagenmann M, et al. Mepolizumab Induced Loss of Smell Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps From the SYNAPSE Study. [Abstract/Poster No. P481].

PRESENTATIONS BY GSK ON TRELEGY IN ASTHMA:

1. Germain G, Settipane RA, Abbott C, et al. Patient Characteristics and Treatment Patterns of Elderly Asthma Patients Initiating FF/UMEC/VI. [Abstract/Poster No. P275].

AAFP 2021

Posters

Shingrix

1. Fiore. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing.Poster F\AAFP 2021

Oral Presentations

Oct 21-25, 2020

1. GSK’S SCIENTIFIC ACTIVITIES AT IDWEEK^™ 2020

2. Individual and State-Level Factors Associated with Receipt of Multiple Recommended Adolescent Vaccines in the US

3. Impact of State Residence on Adult Vaccination Uptake: A Multilevel Modeling Approach

4. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine?

5. Can Recombinant Zoster Vaccine Administration Decrease the Use of HZ-Related Pain Medication Across Randomized Controlled Studies?

6. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against HZ: Interim Results of an Extension Study of Two Clinical Trials

7. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults

Posters

Oct 21-25, 2020

1. #Vaccine Twitter Influencers: Is it Just About Reach and Followers?

2. Factors Associated with Meningococcal Vaccination Among Patients with Newly Diagnosed High-Risk Conditions

3. Two-Dose 4CMenB Vaccination in Adolescents Elicits Bactericidal Activity Against 15 Outbreak-Representative Meningococcal Strains

4. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results

5. Assessment of Recombinant Zoster Vaccine Second-Dose Completion in the United States

6. Economic Burden of Herpes Zoster Among Individuals With COPD: A Retrospective Cohort Study

7. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination

8. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of 6 Trials

9. Concomitant Administration of Liquid Porcine Circovirus-free Human Rotavirus Vaccine with Routine Pediatric Vaccines

Oral Presentations

Apr 27, 2020 | Virtual Annual Meeting I

1. Presentation: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1)

2. Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1)

3. Presentation with Audio: Voice Recording: A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC

Oral Presentation

December 5-8, 2020 | Virtual

1. Part 1 Results of a Dose Finding Study of Belantamab mafodotin (GSK2857916) in Combination with Pomalidomide (POM) and Dexamethasone (DEX) for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Oral Presentation

December 5-8, 2020 | Virtual

Posters

December 5-8, 2020 | Virtual

1. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

2. Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

3. Recovery of Ocular Events with Longer-term Follow-up in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

5. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) – 1-Year Outcomes by Prior Therapies

6. DREAMM-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination With 4 Different Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

7. DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

8. DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

9. DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Pomalidomide and Dexamethasone (B-Pd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

10. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA

11. Exposure–Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

Publication Only: Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data From the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)

Publication Only: Real-world Incidence and Clinical and Economic Burden of Managing Ocular Events (OE) in Patients with Active Multiple Myeloma (MM)

Oral Presentations

September 19-21, 2020 | Virtual

1. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020

2. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer: Results from GARNET

Posters

September 19-21, 2020 | Virtual

1. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020

2. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer: Results from GARNET

3. Efficacy and Safety of Niraparib in Elderly Patients (Pts) with Advanced Ovarian Cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 Trial

4. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP)

5. JASPER: Efficacy and Safety of First-Line (1L) Niraparib Plus a Programmed Death Receptor-1 Inhibitor (PD-1i) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

6. Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab

7. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)

8. Matching-Adjusted Indirect Comparisons (MAIC) of Safety Between Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

9. The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis

10. Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

11. Phase 2 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in platinum-experienced advanced cervical cancer (TiP)

12. A phase 2/3, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (TiP)

13. Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, as second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC)

14. Plain Language Summary [HCP USE ONLY]: The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-Analysis

15. Plain Language Summary [HCP USE ONLY]: GARNET: Results on Dostarlimab in Patients with Recurrent or Advanced dMMR Endometrial Cancer (PROs)

Posters

November 16-19, 2020 | Virtual

1. Economic and Humanistic Outcomes Associated with Treatment of Recurrent or Metastatic Cervical Cancer: A Literature Review

2. Patient Experience Information (PEI) and Patient Involvement in Health Technology Assessment (HTA) Processes in 7 European Countries Using Immuno-Oncology Examples: How Can the Patient Voice Make an Impact?

NY-ESO-1 TCR T Cell (GSK3377794)

Cancer Target Rationale

NY-ESO-1 and LAGE-1a are highly homologous immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients.^1,2
NY-ESO-1 and LAGE-1a are expressed in a wide range of tumor types, with restricted expression in normal tissues.¹

Overview

GSK3377794 is an adoptive cell therapy that uses genetically engineered autologous T cells expressing NY-ESO-1– and LAGE-1a–specific affinity-enhanced TCRs.¹
GSK3377794 is being investigated as a monotherapy and in combination with pembrolizumab in NY-ESO-1– and/or LAGE-1a–positive solid tumors, NSCLC, and relapsed/refractory multiple myeloma.

References:

Thomas R, Al-Khadairi G, Roelands J, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol. 2018;9:947.
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914-921.

Posters

February 27-29, 2020 | Scottsdale, AZ

Real World Immuno-oncology Treatment Patterns and Outcomes in US Patients with Metastatic Head and Neck Cancer

Oral Presentations

October 3-4, 2020 | Virtual

Presentation: DREAMM-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-Directed Immunoconjugate) in Combination With Novel Agents in Relapsed/Refractory Multiple Myeloma (RRMM)

Presentation: DREAMM-2: Pivotal Study Primary Analysis: Single-Agent Belantamab Mafodotin (GSK2857916) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors (PIs), Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs)

Poster

October 3-4, 2020 | Virtual

DREAMM-2: Belantamab Mafodotin (Belamaf) in Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory/Intolerant to Anti-CD38 mAb, Including Subgroups With Renal Impairment (RI) and High-Risk (HR) Cytogenetics

Poster

January 23-25, 2020 | San Francisco, CA

Safety and Efficacy of Anti-PD-1 Antibody Dostarlimab in Patients with Mismatch Repair-Deficient (dMMR) GI Cancers

American College of Rheumatology (ACR) Convergence

November 10-14, 2022 | Hybrid | Philadelphia, PA

Poster

1. Achieving SLE Disease Control or LLDAS and Lower Organ Damage Rates

2. Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)

3. The Effect of Belimumab on Kidney Outcomes in SLE: Results of a Large Integrated Analysis

4. Exploring Canadian Patient Experiences of Living With Lupus Nephritis

5. Real-World Effectiveness of Belimumab in Patients With SLE in the US

Poster

June 2-5, 2021 | Virtual

1. BLISS-LN OLE: A 6-Month Open-Label Extension Study of the Safety and Efficacy of Intravenous Belimumab in Patients With Lupus Nephritis

2. Development of a Conceptual Model to Understand Disease Burden in Patients with Systemic Lupus Erythematosus and Long-Term Organ Damage

3. Epidemiology of Lupus Nephritis in Brazil: Findings From the Macunaíma Study – A Nationwide Multicentric Study

4. Mapping the Nationwide Clinical Profile and Patterns of Care of SLE in Brazil – Findings From the Macunaíma Study

5. Safety and Efficacy of Belimumab in Older Adults with Systemic Lupus Erythematosus: Results of an Integrated Analysis

6. Safety of Belimumab in Adult Patients With Systemic Lupus Erythematosus: A Large Integrated Safety Analysis of Controlled Clinical Trial Data

Poster

June 2-5, 2021 | Virtual

1. Safety and Efficacy of Subcutaneous Belimumab and Intravenous Rituximab Combination Patients with Primary Sjögren’s Syndrome: A Phase 2, Randomized, Placebo-Controlled 68-Week Study

Poster

May 18-20, 2020 | Virtual

1. Real-World Average Dose of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer

Posters

January 28-31, 2021 | Virtual

1. Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study

2. CD8α-enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1

Oral Presentations

May 29-June 2, 2020 | Virtual

1.ORAL PRESENTATION:DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

2. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-6 Study: What Side Effects Were Experienced When Patients With Multiple Myeloma Were Treated With Belantamab Mafodotin in Combination With Another Anti-Myeloma Treatment, Bortezomib/Dexamethasone?

Posters

May 29-June 2, 2020 | Virtual

2. POSTER: Niraparib Exposure-Response Relationship in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC)

3. POSTER: Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study

4. POSTER: Pharmacokinetics and Safety Following a Single Oral Dose of Niraparib in Patients with Moderate Hepatic Impairment

7. POSTER: Belantamab Mafodotin (GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics in DREAMM-2

8. POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM)

9. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment

10. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: What Were the Effects of Belantamab Mafodotin in Patients With Multiple Myeloma and Reduced Kidney Function?

13. POSTER: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

17. ENCORE: Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

19. POSTER: BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II study

20. POSTER: Two-Year Follow-Up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, for Second-Line (2L) Treatment of Non-Small Cell Lung Cancer (NSCLC)

21. PUBLICATION ONLY: Real-World Treatment Patterns of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Patients Missing Out?

22. PUBLICATION ONLY: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting

23. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab

24. PUBLICATION ONLY: DREAMM-1: Patient Perspectives from the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM)

26. PUBLICATION ONLY: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review

27. PUBLICATION ONLY: Qualitative Patient Interviews on Symptoms and Impacts in Metastatic Synovial Sarcoma (mSS)

28. PUBLICATION ONLY: Epidemiology of Adenoid Cystic Carcinoma in the United States

Symposia

May 29-June 2, 2020 | Virtual

SYMPOSIUM: Advances in Targeting of B-cell Maturation Antigen (BCMA) as an Investigational Novel Approach in Multiple Myeloma

IMPORTANT NOTICE

IMPORTANT NOTICE

Oncology